Article Figures & Data
Figures
- Figure 1.
Urine Tubular Protein Markers: 48-Week Analysis
BL, baseline; E/C/F/TAF, elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide; IQR, interquartile range; STB, elvitegravir-cobicistat-emtricitabine-tenofovir disoproxil fumarate.
Reproduced from J Acquir Immune Defic Syndr, Sax PE et al. Tenofovir Alafenamide Vs Tenofovir Disoproxil Fumarate in Single Tablet Regimens for Initial HIV-1 Therapy: A Randomized Phase 2 Study, 2013;67:52–58, Copyright 2013, with permission from Lippincott Williams & Wilkins.
- Figure 2.
GARDEL Results: Viral Load < 50 Copies/mL at Week 48
BSL, baseline; DT, dual therapy; TT, triple therapy.
Reprinted from Lancet Infect Dis, 14, Cahn P et al, Dual Therapy With Lopinavir and Ritonavir Plus Lamivudine Versus Triple Therapy With Lopinavir and Ritonavir Plus Two Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral-Therapy-Naïve Adults With HIV-1 Infection: 48 Week Results of the Randomised, Open Label, Non-Inferiority GARDEL Trial, 572–580, Copyright 2014, with permission from Elsevier Ltd.
Tools
Table of contents
Cited By...
- No citing articles found.